Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > I Wonder

<< Previous

Bullboard Posts

Next >>

Comment by m8magicon Feb 21, 2021 2:42pm

251 Views

Post# 32622143

RE:RE:I Wonder

Pandora wrote:
https://www.biopharmadive.com/news/biotech-pharma-deal-trends-2021/593267/

To: ogi who wrote (24598)	6/2/2014 2:19:35 AM
From: ayeyou	1 Recommendation of 49314

Concordia got the rights to Photofrin when they purchased a private US company called Pinnacle Biologics . How they had obtained the rights from QLT I am not sure as I have been unable to find a lot of info on Pinnacle. What was of interest to me is that the market is putting an almost Billion dollar market cap on CXR. Photofrin is not even effective in low or no oxygen regions where cancer cells are commonly found. That is why the FDA trials showed only a 60% max efficiency for Photofrin. That and the low light penetration of the Photofrin laser system. Also Photofrin patients remain light sensitive for a month after treatment. TLTs PDCs are effective even in the absence of any oxygen and it is my opinion that once the human trials are done TLTs success rate will be heads above Photofrin. This comment from the Professor of Chemistry at Acadia University where the PDCs were developed sums up my thoughts as to where TLT is headed.... Dr. Sherri McFarland, Professor of Chemistry at Acadia University, the originator of the PDCs under worldwide exclusive licence to Theralase stated, "I am truly excited to work with Theralase in the development of these PDCs and be associated with their lead scientists and clinical oncologists to develop the next generation of anti-cancer technology. From the raw research I have observed, this technology has the potential to not only destroy one type of cancer, but many. I am convinced that this technology has the opportunity to go mainstream as a primary treatment in the destruction of cancer, within the next few years."